Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli

Size: px
Start display at page:

Download "Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli"

Transcription

1 CHEST Emergence of New Forms of Totally Drug-Resistant Tuberculosis Bacilli Original Research Super Extensively Drug-Resistant Tuberculosis or Totally Drug-Resistant Strains in Iran Ali Akbar Velayati, MD; Mohammad Reza Masjedi, MD; Parissa Farnia, PhD; Payam Tabarsi, MD; Jalladein Ghanavi, MD; Abol Hassan ZiaZarifi, PhD; and Sven Eric Hoffner, MD TUBERCULOSIS Background: The study documented the emergence of new forms of resistant bacilli (totally drug-resistant [TDR] or super extensively drug-resistant [XDR] tuberculosis [TB] strains) among patients with multidrug-resistant TB (MDR-TB). Methods: Susceptibility testing against first- and second-line drugs was performed on isolated Mycobacterium tuberculosis strains. Subsequently, the strains identified as XDR or TDR M tuberculosis were subjected to spoligotyping and variable numbers of tandem repeats (VNTR). Results: Of 146 MDR-TB strains, 8 XDR isolates (5.4%) and 15 TDR isolates (10.3%) were identified. The remaining strains were either susceptible (67%) or had other resistant patterns (20%). Overall, the median of treatments and drugs previously received by MDR-TB patients was two courses of therapy of 15 months duration with five drugs (isoniazid [INH], rifampicin [RF], streptomycin, ethambutol, and pyrazinamide). The median of in vitro drug resistance for all studied cases was INH and RF. The XDR or TDR strains were collected from both immigrants (Afghan, 30.4%; Azerbaijani, 8.6%; Iraqi, 4.3%) and Iranian (56.5%) MDR-TB cases. In such cases, the smear and cultures remained positive after 18 months of medium treatment with second-line drugs (ethionamide, para-aminosalicylic acid, cycloserine, ofloxacin, amikacin, and ciprofloxacin). Spoligotyping revealed Haarlem (39.1%), Beijing (21.7%), EAI (21.7%), and CAS (17.3%) superfamilies of M tuberculosis. These superfamilies had different VNTR profiles, which eliminated the recent transmission among MDR-TB cases. Conclusions: The isolation of TDR strains from MDR-TB patients from different regional countries is alarming and underlines the possible dissemination of such strains in Asian countries. Now the next question is how one should control and treat such cases. (CHEST 2009; 136: ) Abbreviations: AMK amikacin; anti-tb antituberculosis; CAP capreomycin; Cip ciprofloxacin; CYC cycloserine; DST drug susceptibility test; ETB ethambutol; ETH ethionamide; INH isoniazid; KAN kanamycin; MDR multidrug resistant; NRITLD National Research Institute of Tuberculosis and Lung Diseases; OFX ofloxacin; PAS para-aminosalicylic acid; PTH prothionamide; PZA pyrazinamide; RF rifampicin; SM streptomycin; TB tuberculosis; TDR totally drug resistant; VNTR variable numbers of tandem repeats; XDR extensively drug resistant According to a nationwide survey 1 conducted in Iran (1999), among all Mycobacterium tuberculosis isolates tested for drug susceptibility, 10.9% were resistant to one or more antituberculosis (anti- TB) drugs and 6.7% were resistant to both isoniazid (INH) and rifampin (RF) [ie, they were multidrugresistant (MDR) strains of M tuberculosis]. In further studies, 2 we documented the existence and transmission of extensively drug-resistant (XDR) tuberculosis (TB) among patients with MDR-TB. These strains were identified as belonging to the Beijing and Haarlem I superfamilies of M tuberculosis. 3 By definition the XDR-TB bacilli are resistant to fluoroquinolone and to any of three injectable drugs (capreomycin [CAP], kanamycin [KAN], and amikacin [AMK]) in addition to INH and RF. 4,5 420 Original Research

2 Recent investigation 6,7 on six different continents showed that 10% of MDR-TB cases became XDR-TB strains. Although the problem of XDR-TB cases remains unresolved in much of the world, here we report on more dangerous forms of the disease, which we call totally drug-resistant strains (TDR) or super XDR-TB isolates. We define TDR as MDR strains that are resistant to all second-line drug classes that our laboratory tested (ie, aminoglycosides, cyclic polypeptides, fluoroquinolones, thioamides, serine analogues, and salicylic acid derivatives). Furthermore, to gain a better appreciation of the epidemiology of these strains in Iran, classical and molecular epidemiologic techniques were utilized. To our knowledge, this is the first report that describes the prevalence of TDR among patients with MDR-TB. Setting Materials and Methods The National Research Institute of Tuberculosis and Lung Diseases (NRITLD) (Tehran, Iran) acts as the sole national referral center for TB in Iran. Located inside the NRILTD is a National Reference Tuberculosis Laboratory, which is under the technical supervision of the Supranational Reference Laboratories of the Swedish Institute for Infectious Diseases Control (Solna, Sweden). Under the National Tuberculosis Control program, all the MDR and relapse cases of TB are referred to the NRITLD for evaluation and treatment. The institutional review board at the NRITLD approved the study. Patients According to the Iranian National Tuberculosis Control treatment protocol, all new TB patients receive the World Health Organization category I regimen or, in case of relapse or failure, the category II regimen. If category II treatment fails, patients Manuscript received October 25, 2008; revision accepted February 4, Affiliations: From the Mycobacteriology Research Centre (Drs. Velayati, Farnia, Masjedi, and ZiaZarifi), Animal Research Laboratory (Dr. Ghanavi), the National Research Institute of Tuberculosis and Lung Disease (NRITLD), World Health Organization Collaborating Centre, Shahid Beheshti University (Medical Campus), Darabad, Tehran, Iran; and the Department of Bacteriology (Dr. Hoffner), Swedish Institute for Infectious Disease Control, Solna, Sweden. Funding/Support: This research was funded by the Medical Research Council/National Research Institute of Tuberculosis and Lung Disease/World Health Organization grant No American College of Chest Physicians. Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( misc/reprints.xhtml). Correspondence to: Parissa Farnia, PhD, Mycobacteriology Centre, NRITLD/WHO, Shahid Beheshti University (Medical Campus), Tehran, 19556, PO 19575/154, Iran; pfarnia@ nritld.ac.ir or pfarnia@hotmail.com DOI: /chest are referred to the NRITLD. In addition to these cases, some patients were directly referred to us. These patients (12 MDR cases and 1 XDR-TB case) had no previous history of TB. Patients With MDR-TB Inclusion criteria for patients with MDR-TB were a history of at least one previous period of TB treatment, two positive sputum smear test results, and a positive sputum culture result Patients were also required to have drug susceptibility test (DST) results that showed resistance to INH and RF, as well as chest radiograph findings and clinical symptoms that were compatible with pulmonary TB. Treatment Because no patients with TB in Iran receive second-line drugs, MDR-TB patients are assumed to be susceptible to second-line agents, which are considered active. All the patients received at least 6 months of an injectable aminoglycoside (eg, AMK at a dose of 15 mg/kg), which was continued for at least 4 months after the culture turned negative or adverse effects to the drug developed. Patients first underwent an intermediate regimen comprising four second-line drugs: ofloxacin (OFX) [400 to 800 mg/d], cycloserine (CYC) [750 to 1,000 mg/d], prothionamide (PTH) [750 to 1,000 mg/d], and AMK (15 mg/kg/d, 5 d/wk; maximum, 1 g/d) until the results of a DST were available. The regimen was then modified on the basis of DST so that all first-line drugs to which they were susceptible were included in combination with at least four active second-line drugs. If major adverse effects occurred, the suspected agent was replaced by other drugs, such as clarithromycin or amoxicillin-clavulanate, which may be of unproven efficacy but are recommended as the fifth group of anti-tb agents by the World Health Organization for the management of MDR-TB when other agents are not available or cannot be used. After discharge from the hospital, follow-up evaluation included a sputum smear and culture every month and a chest radiograph every 3 months. For TDR cases (clinically and laboratory approved), either co-amoxiclav (625 mg/8 h) or clarithromycin (1,000 mg/d), along with a high dose of INH (15 mg/kg), were prescribed without any improvement. Bacterial Strain Primary isolation and culturing of Mycobacterium isolates from sputum specimens were followed in accordance with the procedures manual. 11 All isolates were identified as M tuberculosis by using biochemical tests, including production of niacin, catalase activity, nitrate reduction, pigment production, and growth rate. DST against INH, RF, streptomycin (SM), and ethambutol (ETB) were performed by the proportional method on Löwenstein- Jensen media at a concentration of 0.2, 40, 4.0, and 2.0 g/ml, respectively. 11 Susceptibility to pyrazinamide (PZA) [900 and 1,200 g/ml] was tested using a two-phase medium where the strain was reported to be resistant to PZA if, on day 21, the proportion of drug-resistant colonies was higher than the defined critical proportion. DST against second-line drugs (CAP, 10 g/ml; KAN, 20 g/ml; ethionamide [ETH], 20 g/ml; OFX, 2 g/ml; ciprofloxacin [Cip], 2 g/ml; CYC, 30 g/ml; AMK, 4 g/ml; and para-aminosalicylic acid [PAS], 5 g/ml) was performed on all MDR strains using two critical proportions of 1% and 10%. 12 TDR strains were resistant to all first- and second-line drugs tested. Overall, the DST against first- and secondline drugs was performed on the first culture-positive specimen that was collected from MDR-TB patients prior to starting treatment at the NRITLD. In the case of XDR or TDR reports, the DST was CHEST / 136 / 2/ AUGUST,

3 repeated 6 to 8 months after starting the treatment with second-line drugs. (The XDR or TDR strains discussed here had a similar pattern of resistance in the first and second DST). Spoligotyping The extraction of bacterial DNA was performed with standard protocols. 13 For spoligotyping, the direct repeat region was amplified by polymerase chain reaction (PCR) using primers derived from the direct repeat sequence (Isogen Bioscience; Maarssen, the Netherlands). The amplified DNA was hybridized to a set of 43 immobilized oligonucleotides derived from the spacer sequences of M tuberculosis H37RV and Myobacterium bovis BCG P3 by reverse line blotting. Variable Numbers of Tandem Repeats Typing Variable numbers of tandem repeats (VNTR)-PCR primers were designed as described by Frothingham and Meeker- O Connell. 14 PCRs were run in DNA thermal cyclers (model 480; Perkin Elmer; Golden Valley, MN) under the following conditions: 95 C for 12 min, 40 cycles of 94 C for 30 s, 60 C for 1 min, and 72 C for 2 min, followed by final extension at 72 C for 7 min. PCR products were analyzed by agarose gel electrophoresis. The number and size of repeat units in H 37 RV(bp) for MPTR-A, ETR-A, ETR-B, ETR-C, ETR-D, ETR-E, and ETR-F were as follows: 16 15, (3 75) 23, (3 57) 8, (4 58) 21, (3 77) 7, (3 53) 1, (3 79) 13, respectively. 14 Computer-Assisted Analysis of Fingerprints The autoradiograph of spoligotyping was scanned with the Snap Scan 1236 Scanner (AGFA; Sint-Martens-Latem, Belgium). Bionumerics Software, version 2.5 (Applied Maths; Kortrijk, Belgium) was used to analyze the molecular patterns generated by spoligotyping. Strains were classified as a cluster if they shared similar spoligopatterns and VNTR profiles. Statistical Analysis The continuous variables were expressed as group means ( SD). The variables included sex, age, the pattern of drug resistance, the result of a purified protein derivative, and HIV between XDR- and TDR-TB patients. Study Population Results From October 2006 to October 2008, 166 MDR-TB patients were referred to the NRITLD for treatment and diagnosis. Of these patients, 20 patients (12%) had infection with mycobacterium other than tuberculosis. The results of susceptibility against first-line drugs were improved resistance to INH and RF in the remaining MTB isolates (n 146). The results of susceptibility against second-line drugs were as follows: 65 strains (44.5%) were susceptible to all drugs tested, 8 strains were XDR (5.4%), and 15 strains were TDR isolates (10.2%). The remaining strains (n 58; 36.7%) had other resistance. Table 1 shows the demographic characteristics of XDR and Table 1 Demographic Data of Studied TB Cases Variables All MDR-TB Cases (n 146) XDR-TB Cases (n 8) Super XDR-TB Cases (n 15) Nationality Iranian 78 (53.4) 4 (50) 9 (60) Afghani 65 (44.5) 2 (25) 5 (33.3) Other immigrants 3 (2.0) 2 (25) 1 (6.6) Age, yr Gender Male 79 (54.1) 5 (62.5) 12 (80) Female 67 (45.8) 3 (37.5) 3 (25) AIDS Positive 2 (1.3) Negative 60 (41.0) 8 (100) 15 (100) Not available 84 (57.5) Involvement Pulmonary diseases 140 (95.8) 8 (100) 15 (100) Extrapulmonary disease Both 6 (4.1) TB history New: smear 12 (8.2) 1 (12.5) positive Old: TB cases 134 (91.7) 7 (87.5) 15 (100) Purified protein derivative Positive 43 (29.4) 4 (50) 5 (33.3) Negative 21 (14.3) 3 (37.5) 7 (46.6) Equivocal 71 (48.6) 1 (12.5) 3 (20) Not available 11 (7.5) Values are given as No. (%) or mean SD. TDR TB. The majority of them (95.6%) had a previous history of TB, and all of them had negative HIV test results (100%). The male-to-female ratio was more than threefold in TDR cases (p 0.05). The median ages in MDR, XDR, and TDR patients were , , and years, respectively. Although the immigrants with XDR or TDR-TB isolates were much younger than Iranian patients (average age, 34.5 vs 61.2 years, respectively), the differences were statistically significant (p 0.05). The XDR and TDR Afghan immigrants were living in Iran and had been frequently traveling in and out of the country. The other TDR immigrants (two Azerbaijani and one Iraqi) had been referred to the NRITLD for diagnosis and treatment. Overall, the medians of treatments and drugs previously received by the MDR-TB patients was two courses of therapy in 15 months with five drugs (INH, RF, SM, ETB, and PZA), respectively. The medians of in vitro drug resistance for all studied cases were INH and RF. In the TDR cases, the smear and cultures remained positive after 18 months of treatment with second-line drugs. Changing the treatment to co-amoxiclav (625 mg/8 h) or clarithromycin (1,000 mg/d), along with high dose of INH (15 mg/kg), made no improvement in them. 422 Original Research

4 Spoligopatterns and VNTR Profiles When the spoligotypes from the isolated XDR and TDR M tuberculosis strains were compared with earlier published spoligotypes, our isolates could be identified as members of the superfamilies Haarlem I (n 9; 39.1%), Beijing (n 5; 21.7%), EAI (n 5; 21.7%), and CAS (n 4; 17.5%) [Table 2]. The VNTR profiles of spoligotypes strains were different in each superfamily (Table 2). The five isolated Beijing families had , , , , and profiles. Similarly, the Haarlem I family had different profiles ( , , , , , , , , and ). The different VNTR profiles patterns dismissed the possibility of recent transmission among XDR- or TDR-TB cases. Discussion This study represents the first report on the existence and prevalence of TDR strains in Iran. TDR strains not only constitute a deadly threat to the affected patients with TB but also hamper the TB-control program. Previously, we identified two clusters of XDR-TB isolates in both family and community outbreaks. 2 These strains were fully capable of being transmitted and causing active diseases in individuals with secondary cases. In the present report, 95% of XDR and TDR strains were isolated from patients with a previous history of TB. In this study, XDR-TB was defined as MDR isolates with a further resistance to fluoroquinolone and to at least one of the three injectable drugs used Table 2 Spoligotyping Patterns and VNTR Profiles of XDR and TDR Patients Patient No. Age, yr Gender Nationality Previous History of TB Susceptibility Drugs Yielding In Vitro Resistance Spoligotyping VNTR Profiles 1 48 M Iranian Yes XDR-TB INH, RF, CAP, Cip, OFX Haarlem I F Iranian No XDR-TB INH, RF, KAN, AMK, Cip Beijing M Iranian Yes XDR-TB INH, RF, CAP, OFX, Cip CASI F Iraqi Yes XDR-TB INH, RF, KAN, Cip EAI M Iranian Yes XDR-TB INH, RF, KAN, CAP, Cip Haarlem I M Iranian Yes XDR-TB INH, RF, CAP, Cip, OFX EAI F Afghani Yes XDR-TB INH, RF, CAP, Cip, OFX Beijing F Afghani Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, CASI M Iranian Yes TDR-TB INH, RF,SM, ETB, PZA, CAP, KAN, EAI M Iranian Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Haarlem I M Iranian Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Haarlem I M Iranian Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, EAI M Iranian Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, CASI M Afghani Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Beijing M Afghani Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Haarlem I F Azerbaijani Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Beijing M Iranian Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Haarlem I F Iranian Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, CASI M Afghani Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, EAI M Afghani Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Haarlem I F Azerbaijani Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Haarlem I M Iranian Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Haarlem I F Afghani Yes TDR-TB INH, RF, SM, ETB, PZA, CAP, KAN, Beijing M male; F female. CHEST / 136 / 2/ AUGUST,

5 in anti-tb treatment. TDR was defined as M tuberculosis isolates that were resistant to all first-line (INH, RF, SM, ETB, and PZA) and second-line drugs tested (OFX, CYC, PTH, AMK, KAN, ETH, PAS, and CAP). Generally, the spectrum of resistance reflects the drugs that the patients have used and the way in which therapy was controlled. 9,15 The Iranian TDR-TB patients had not received second-line drugs before being admitted to the NRITLD. But to our surprise, 10.2% of these strains showed resistance to all the second-line drugs tested. In Iran, some of the second-line drugs (ie, aminoglycosides and fluoroquinolones) are routinely used for the treatment of respiratory diseases other than TB. It is most likely that these patients had been treated previously with aminoglycosides and fluoroquinolones in a poorly controlled manner. In contrast, the other drugs (ie, CAP and PAS) were introduced to Iran beginning in 2002, and none of the Iranian TDR patients had a previous history of receiving such drugs. At present, we do not know why some of the MDR-TB strains showed resistance to second-line drugs, but the possibility of sequential mutations is highlighted and is under investigation in our laboratory. In this study, 43% of XDR and TDR strains belonged to immigrants living in Iran or who had visited the country. These patients did not have a proper clinical history, and the possibility they had received second-line drugs could not be ignored. We have already shown that 32% of the initial TB patients referred to our unit were Afghan-born immigrants. 16 The majority of them (58%) had either resistance to any drug or to a drug combination including MDR-TB. 16 The incidence of intracommunity transmission between Iranian and Afghan patients rose significantly, from 13 to 41%, from 2005 to These findings highlight the need to adopt new strategies with regard to screening immigrants from neighboring countries, which is absent in the current system. The isolated strains belonged to different superfamilies of M tuberculosis, that is, Haarlem (39.1%), Beijing (21.7%), EAI (21.7%), and CAS (17.3%). The Haarlem I and Beijing were the most frequent superfamilies among MDR-TB patients. 16,17 The Haarlem I and Beijing strains have been reported in different geographic regions of the world, and they are thought to possess selective advantages in comparison with other M tuberculosis. 17,18 In the present study, 60% of patients were infected with the Haarlem I or Beijing superfamily. Therefore, it is clear that both these superfamilies can cause an epidemic, and from an epidemiologic point of view, it is necessary to conduct more extensive surveillance of MDR-TB strains because they might cause serious outbreaks. 2 Further epidemiologic studies 17 using VNTR techniques showed different VNTR profiles among identified superfamilies. This means the studied strains probably were not transmitted via recent transmission but rather seemed to have developed due to the failure of the current recommended policies and protocols initially to diagnose, treat, and cure such cases adequately. This assertion is supported by the finding of only a single patient with new XDR-TB (not receiving previous treatment) among the studied cases (Table 2). The isolation of TDR strains from MDR-TB patients who belonged to different regional countries is alarming, and it underlines the possible dissemination of such strains in Asian countries. A 2004 population-based study 4 of drug susceptibility among isolates from patients with TB showed that 4%, 19%, and 15% of MDR-TB cases in the United States (1993 to 2004), Latvia (2000 to 2002), and South Korea (2004), respectively, were XDR TB. However, what percentages of MDRTB are TDR is not known. Today, the most important question is how to control and prevent the transmission of such deadly bacilli regionally and globally. 19 And what combination of drugs has to be used for these patients? Based on standard protocols, if a patient has an isolate that is resistant to all but two or three relatively weak drugs, the patient should undergo surgery. However, in our study, surgery was not applicable (because of extensive and diffused lung damage in such cases), and the patients were receiving either co-amoxiclav (625 mg/8 h) or clarithromycin (1,000 mg/d), along with a high dose of INH (15 mg/kg) without any improvement. This problematic situation illustrates an urgent need to find an effective medicine for treating such complicated cases. Our study was limited to patients who were referred to the NRITLD, and it cannot represent the overall situation in the country. Possibly the condition is worse in provinces near the borders (until now we have found no recent transmission of TDR-TB cases within the country). Therefore, further research is required to determine the prevalence of such type of TB bacilli not only in Iran but also in nearby countries (ie, Afghanistan, Pakistan, Iraq, and the former Soviet Union). Indeed, we have to achieve a clear picture about the spread and transmission of TDR bacilli within these countries. In conclusion, the emergence of TDR bacilli is a worrisome development, and it clearly underlines the urgent need to reinforce the Iranian TB-control policy, with special attention to the prompt and reliable laboratory detection of drug-resistant TB, as well as the need for efficient infection-control measures to stop or strongly limit the spread of TDR M tuberculosis. 424 Original Research

6 Acknowledgments Author contributions: Drs. Velayati and Masjedi participated in the study conception and manuscript review. Dr. Farnia designed and implemented the study, and wrote the manuscript. Drs. Tabarsi, Ghanavi, ZiaZarifi, and Hoffner reviewed the data and manuscript. Financial/nonfinancial disclosures: The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Other contributions: We thank the TB patients and their families who helped us complete the required information. References 1 World Health Organization (WHO). Stop TB partnership annual report Available at: WHO_HTM_STB_ _eng.pdf. Accessed April 20, Masjedi MR, Farnia P, Sorooch S, et al. Extensively drugresistant tuberculosis: 2 years of surveillance in Iran. Clin Infect Dis 2006; 43: Velayati AK, Farnia P, Mirsaeidi, et al. The most prevalent Mycobacterium tuberculosis superfamilies among Iranian and Afghan TB cases. Scand J Infect Dis 2006; 38: Centers for Diseases Control and Prevention. Emergence of Mycobacterium tuberculosis with extensive resistance to second line drugs worldwide, MMWR Morb Wkly Rep 2006; 55: Lawn SD, Wilkinson R. Extensively drug resistant tuberculosis. BMJ 2006; 333: Blass SH, Mutterlein R, Weig J, et al. Extensively drug resistant tuberculosis in a high income country: a report of four unrelated cases. BMC Infect Dis 2008; 8: Zignol M, Hosseini M, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis 2006; 194: World Health Organization. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance Geneva, Switzerland: World Health Organization, 2000; Grant A, Gothard P, Thwaites G. Managing drug resistant tuberculosis. BMJ 2008; 337: Mirsaeidi MS, Tabarsi P, Farnia P, et al. Trends of drug resistant Mycobacterium tuberculosis in a tertiary tuberculosis center in Iran. Saudi Med J 2007; 28: Kent PT, Kubica GP. Public health mycobacteriology: a guide for a level III laboratory. Atlanta, GA: Public Health Services, U.S. Department of Health and Human Services, Guidelines for drug susceptibility testing for second-line anti-tuberculosis drugs for DOTS-plus. Geneva, Switzerland: World Health Organization, Available at: who.int/hq/2001/who_cds_tb_ pdf. Accessed April 20, van Embden JD, Cave MD, Crawford JT, et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendation for a standardized methodology. J Clin Microbiol 1993; 31: Frothingham R, Meeker-O Connell W. Genetic diversity in the MTB complex based on variable numbers of tandem DNA repeats. Microbiology 1998; 144: Mitchison DA. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: Farnia P, Masjedi MR, Mirsaeidi M, et al. Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients. J Infect 2006; 53: Farnia P, Masjedi MR, Varahram M, et al. The recent transmission of Mycobacterium tuberculosis strains among Iranian and Afghan relapse cases: a DNA-fingerprinting using RFLP and spoligotyping [abstract]. BMC Infect Dis 2008; 8: Brudey K, Driscoll JR, Rigouts L, et al. Mycobacterium tuberculosis complex genetic diversity: mining the fourth international spoligotyping database (spoldb4) for classification, population genetics and epidemiology. BMC Microbiol 2006; 6: Moszynski P. Doctors disagree over detention of patients with extensively drug resistant tuberculosis [abstract]. BMJ 2007; 334:228 CHEST / 136 / 2/ AUGUST,

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Mitnick CD, Shin SS, Seung KJ, et al. Comprehensive treatment

More information

Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview

Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview Human Journals Review Article August 2016 Vol.:1, Issue:3 All rights are reserved by Mr. Suraj Narayan Mali et al. Totally Drug-Resistant Tuberculosis (TDR-TB): An Overview Keywords: Totally Drug-resistant

More information

Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients

Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients Journal of Infection (2006) 53, 331e336 www.elsevierhealth.com/journals/jinf Prevalence of Haarlem I and Beijing types of Mycobacterium tuberculosis strains in Iranian and Afghan MDR-TB patients Parissa

More information

Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside of the Czech Republic

Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside of the Czech Republic The Journal of International Medical Research 2010; 38: 1156 1163 [first published online as 38(3) 26] Factors Associated with Multidrugresistant Tuberculosis: Comparison of Patients Born Inside and Outside

More information

Transmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University

Transmission of MDR/XDR Tuberculosis in Shanghai. Qian Gao Shanghai Medical College Fudan University Transmission of MDR/XDR Tuberculosis in Shanghai Qian Gao Shanghai Medical College Fudan University Drug Resistant TB in China The Highest DR-TB Burden Country New TB cases/year Cases with any DR MDR XDR

More information

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos Global epidemiology of drug-resistant tuberculosis Factors contributing to the epidemic of MDR/XDR-TB CHIANG Chen-Yuan MD, MPH, DrPhilos By the end of this presentation, participants would be able to describe

More information

Management of Drug-resistant Tuberculosis (DR-TB)

Management of Drug-resistant Tuberculosis (DR-TB) Management of Drug-resistant Tuberculosis (DR-TB) Nitipatana Chierakul Division of Respiratory Disease & Tuberculosis Department of Medicine Faculty of Medicine Siriraj Hospital October 14 th, 2008 Tropical

More information

Managing Complex TB Cases Diana M. Nilsen, MD, RN

Managing Complex TB Cases Diana M. Nilsen, MD, RN Managing Complex TB Cases Diana M. Nilsen, MD, RN Director of Medical Affairs NYC Department of Health & Mental Hygiene Bureau of TB Control Case #1 You are managing a patient who was seen at a private

More information

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic MULTIDRUG- RESISTANT TUBERCULOSIS Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic I have no relevant financial relationships. Discussion includes off label use of: amikacin

More information

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area

Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area Rapid communications Multidrug- and extensively drug-resistant tuberculosis: a persistent problem in the European Union European Union and European Economic Area C Ködmön (csaba.kodmon@ecdc.europa.eu)

More information

Received 27 August 2010; received in revised form 9 November 2010; accepted 16 November 2010

Received 27 August 2010; received in revised form 9 November 2010; accepted 16 November 2010 Journal of Infection and Public Health (2011) 4, 41 47 First insight into the drug resistance pattern of Mycobacterium tuberculosis in Dohuk, Iraq: Using spoligotyping and MIRU-VNTR to characterize multidrug

More information

Diagnosis of drug resistant TB

Diagnosis of drug resistant TB Diagnosis of drug resistant TB Megan Murray, MD, ScD Harvard School of Public Health Brigham and Women s Hospital Harvard Medical School Broad Institute Global burden of TB 9 million new cases year 2 million

More information

The authors assessed drug susceptibility patterns

The authors assessed drug susceptibility patterns Drug Resistance Among Tuberculosis Patients, 1991 and 1992 New York City, CYNTHIA R. DRIVER, RN, MPH THOMAS R. FRIEDEN, MD, MPH ALAN B. BLOCH, MD, MPH IDA M. ONORATO, MD All the authors are with the Division

More information

Treatment of Active Tuberculosis

Treatment of Active Tuberculosis Treatment of Active Tuberculosis Jeremy Clain, MD Pulmonary & Critical Care Medicine Mayo Clinic October 16, 2017 2014 MFMER slide-1 Disclosures No relevant financial relationships No conflicts of interest

More information

PATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA

PATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA PATTERNS OF DRUG RESISTANCE AND RFLP ANALYSIS OF MYCOBACTERIUM TUBERCULOSIS STRAINS ISOLATED FROM RECURRENT TUBERCULOSIS PATIENTS IN SRI LANKA DN Magana-Arachchi 1, AJ Perera 1, V Senaratne 2 and NV Chandrasekharan

More information

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH. The image part with relationship ID rid2 was not found in the file. MDR TB Management Review of the Evolution (or Revolution?) Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist,

More information

Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB

Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB Eur Respir J 2009; 33: 1085 1094 DOI: 10.1183/09031936.00155708 CopyrightßERS Journals Ltd 2009 Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TB K. Kliiman and

More information

Diagnosis and Treatment of Tuberculosis, 2011

Diagnosis and Treatment of Tuberculosis, 2011 Diagnosis of TB Diagnosis and Treatment of Tuberculosis, 2011 Alfred Lardizabal, MD NJMS Global Tuberculosis Institute Diagnosis of TB, 2011 Diagnosis follows Suspicion When should we Think TB? Who is

More information

Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011

Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011 Original Research Prevalence of resistance to second-line tuberculosis drug among multidrugresistant tuberculosis patients in Viet Nam, 2011 Hoa Binh Nguyen, ab Nhung Viet Nguyen, ac Huong Thi Giang Tran,

More information

The Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public Hospital in Busan

The Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public Hospital in Busan Korean J Fam Med. 2012;33:372-380 http://dx.doi.org/10.4082/kjfm.2012.33.6.372 The Clinical Characteristics and Predictors of Treatment Success of Pulmonary Tuberculosis in Homeless Persons at a Public

More information

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan

Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Journal of Basic & Applied Sciences, 2018, 14, 107-112 107 Study of Multi-Drug Resistance Associated with Anti-Tuberculosis Treatment by DOT Implementation Strategy in Pakistan Sana Saeed 1, Moosa Raza

More information

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016 Recognizing MDR-TB in Children Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention 17-18 February 2016 Objectives Review the definitions and categorization of drugresistant tuberculosis Understand the

More information

Supplementary Appendix

Supplementary Appendix Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Günther G, Lange C, Alexandru S, et al. Treatment outcomes

More information

Ken Jost, BA, has the following disclosures to make:

Ken Jost, BA, has the following disclosures to make: Diagnosis of TB Disease: Laboratory Ken Jost, BA May 10, 2017 TB Intensive May 9-12, 2017 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Ken Jost, BA, has the following disclosures to make: No conflict

More information

What can be done against XDR-TB?

What can be done against XDR-TB? What can be done against XDR-TB? Dr Matteo Zignol Stop TB Dep. World Health Organization Geneva 16 th Swiss Symposium on tuberculosis Münchenwiler, 22 March 2007 XDR-TB Extensive Drug Resistance XDR =

More information

NIH Public Access Author Manuscript Int J Tuberc Lung Dis. Author manuscript; available in PMC 2013 August 06.

NIH Public Access Author Manuscript Int J Tuberc Lung Dis. Author manuscript; available in PMC 2013 August 06. NIH Public Access Author Manuscript Published in final edited form as: Int J Tuberc Lung Dis. 2013 May ; 17(5): 624 629. doi:10.5588/ijtld.12.0792. Outcomes of children treated for tuberculosis with second-line

More information

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB BASICS: PRIORITIES AND CLASSIFICATIONS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE NOVEMBER 1-4, 2016 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1.

More information

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis YAM Wing-Cheong 任永昌 Department of Microbiology The University of Hong Kong Tuberculosis Re-emerging problem in industrialized countries

More information

Spread of Strain W, a Highly Drug-Resistant Strain of Mycobacterium tuberculosis, Across the United States

Spread of Strain W, a Highly Drug-Resistant Strain of Mycobacterium tuberculosis, Across the United States 85 Spread of Strain W, a Highly Drug-Resistant Strain of Mycobacterium tuberculosis, Across the United States Tracy B. Agerton, Sarah E. Valway, Richard J. Blinkhorn, Kenneth L. Shilkret, Randall Reves,

More information

DRUG RESISTANCE IN TUBERCULOSIS

DRUG RESISTANCE IN TUBERCULOSIS DRUG RESISTANCE IN TUBERCULOSIS INTRODUCTION Up to 50 million people may be infected with drug-resistant resistant TB.* Hot zones of MDR-TB such as Russia, Latvia, Estonia, Argentina and the Dominican

More information

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition Pulmonary Tuberculosis Debra Mercer BSN, RN, RRT Definition Tuberculosis is a contagious bacterial infection of the lungs caused by Mycobacterium Tuberculosis (TB) Etiological Agent: Mycobacterium Tuberculosis

More information

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 TB Nurse Case Management San Antonio, Texas April 1 3, 2014 Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014 Ken Jost, BA has the following disclosures to make: No conflict of interests No relevant

More information

March 24, 2007 will mark the 125th anniversary of Robert

March 24, 2007 will mark the 125th anniversary of Robert Eur Respir J 2007; 29: 423 427 DOI: 10.1183/09031936.00001307 CopyrightßERS Journals Ltd 2007 EDITORIAL 125 years after Robert Koch s discovery of the tubercle bacillus: the new XDR-TB threat. Is science

More information

DNA FINGERPRINTING. Barry N. Kreiswirth, PhD Director, PHRI TB Center

DNA FINGERPRINTING. Barry N. Kreiswirth, PhD Director, PHRI TB Center DNA FINGERPRINTING Barry N. Kreiswirth, PhD Director, PHRI TB Center Molecular Epidemiology Local Epidemiology Are M. tuberculosis isolates recovered from localized cases of disease the same or different

More information

Tuberculosis Disparity Between US-born African-Americans and Caucasians in Houston:

Tuberculosis Disparity Between US-born African-Americans and Caucasians in Houston: Tuberculosis Disparity Between US-born African-Americans and Caucasians in Houston: A population-based study Jose A. Serpa 1, M.D.; Larry D. Teeter 2, Ph.D., James M. Musser 2, M.D., Ph.D. and Edward A.

More information

TB Laboratory for Nurses

TB Laboratory for Nurses TB Laboratory for Nurses Shea Rabley, RN, MN Consultant Mayo Clinic Center for Tuberculosis 2014 MFMER slide-1 Disclosures None 2014 MFMER slide-2 Objectives Participants will be able to: 1. Name 2 safety

More information

Multi-drug Resistant Tuberculosis in Rajshahi District

Multi-drug Resistant Tuberculosis in Rajshahi District TAJ December 2005; Volume 18 Number 2 ISSN 1019-8555 The Journal of Teachers Association RMC, Rajshahi Original Article Multi-drug Resistant Tuberculosis in Rajshahi District M Wasim Hussain, 1 M Azizul

More information

Research in Tuberculosis: Translation into Practice

Research in Tuberculosis: Translation into Practice Case History Research in Tuberculosis: Translation into Practice This is a 6-year6 year-old Bosnian male, who presented to ER with one-week history of fever and occasional vomiting. No cough, difficulty

More information

Qian Gao Fudan University

Qian Gao Fudan University Qian Gao Fudan University Outline Background & Objectives Genotyping methods Establish the epidemiological field sites Preliminary results of Molecular epidemiology of TB in China Molecular epidemiology

More information

Marcos Burgos, MD has the following disclosures to make:

Marcos Burgos, MD has the following disclosures to make: Guidelines for the Treatment of Tuberculosis Marcos Burgos, MD May 13, 2015 TB for Pulmonologist March 13, 2015 Phoenix, AZ EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures

More information

Transmission of MDR and XDR Tuberculosis in Shanghai, China

Transmission of MDR and XDR Tuberculosis in Shanghai, China Transmission of MDR and XDR Tuberculosis in Shanghai, China Ming Zhao 1,2., Xia Li 2., Peng Xu 1,2, Xin Shen 1, Xiaohong Gui 1, Lili Wang 1, Kathryn DeRiemer 3, Jian Mei 1 *, Qian Gao 2 * 1 Department

More information

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018 Antimycobacterial drugs Dr.Naza M.Ali lec 14-15 6 Dec 2018 About one-third of the world s population is infected with M. tuberculosis With 30 million people having active disease. Worldwide, 9 million

More information

7. Are you currently engaged in research that could support new TB diagnostic assay development? Yes No

7. Are you currently engaged in research that could support new TB diagnostic assay development? Yes No Determining Future TB Reference Material Requirements WHO/TDR TB Expert & End-User Survey Properly handled samples from well-characterized patients with suspected tuberculosis from disease endemic countries

More information

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer

Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Tuberculosis in the 21 st Century Scott Lindquist MD MPH Tuberculosis Medical Consultant Washington State DOH and Kitsap County Health Officer Feedback Poll In my opinion, the recent media coverage of

More information

Therapeutic drug monitoring (TDM) is the process. Use of Therapeutic Drug Monitoring for Multidrug-Resistant Tuberculosis Patients*

Therapeutic drug monitoring (TDM) is the process. Use of Therapeutic Drug Monitoring for Multidrug-Resistant Tuberculosis Patients* Use of Therapeutic Drug Monitoring for Multidrug-Resistant Tuberculosis Patients* Jiehui Li, MBBS, MS; Joseph N. Burzynski, MD, MPH; Yi-An Lee, MPH; Debra Berg, MD; Cynthia R. Driver, RN, MPH; Renee Ridzon,

More information

Mycobacterium tuberculosis and Molecular Epidemiology: An Overview

Mycobacterium tuberculosis and Molecular Epidemiology: An Overview Journal of Microbiology Research 2014, 4(6A): 25-31 DOI: 10.5923/s.microbiology.201401.04 Mycobacterium tuberculosis and Molecular Epidemiology: An Overview Asho Ali Department of Biology, King Abdul Aziz

More information

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis.

Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Title: Meta-analysis of Individual patient Data (IPD) of Patients with INH (mono or poly-drug) Resistant Tuberculosis. Principal Investigator: Dick Menzies, MD Evidence base for treatment of INH resistant

More information

MDR TB. Jaime C. Montoya MD, MSc

MDR TB. Jaime C. Montoya MD, MSc MDR TB Jaime C. Montoya MD, MSc Definitions of MDRTB and XDRTB Historical background of the problem Global and Philippine Data on MDRTB Risk Factors Diagnosis Treatment Research Gaps Guidelines for the

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis Marcos Burgos, MD April 5, 2016 TB Intensive April 5 8, 2016 San Antonio, TX EXCELLENCE EXPERTISE INNOVATION Marcos Burgos, MD has the following disclosures to make: No conflict

More information

TB the basics. (Dr) Margaret (DHA) and John (INZ)

TB the basics. (Dr) Margaret (DHA) and John (INZ) TB the basics (Dr) Margaret (DHA) and John (INZ) Question 1 The scientist who discovered M. tuberculosis was: A: Louis Pasteur B: Robert Koch C: Jean-Antoine Villemin D: Calmette and Guerin Question 2

More information

VNTR . VNTR. VNTR. (Original Article) PCR-RFLP ( ETR-B, ETR-C, ETR-D, ETR-E, ETR-F : 7 .VNTR : : (Atypical Mycobacteria)

VNTR . VNTR. VNTR. (Original Article) PCR-RFLP ( ETR-B, ETR-C, ETR-D, ETR-E, ETR-F : 7 .VNTR : : (Atypical Mycobacteria) 90 11 3 (Original Article) 4 3 2 1 1. 2. 3. 4. (Non- Tuberculosis Mycobacterium, NTM) :.. (Variable Number Tandem Repeat, VNTR). VNTR ) 48 : PCR-RFLP ( MPTR-A, ETR-A, ETR-B, ETR-C, ETR-D, ETR-E, ETR-F

More information

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER Outline Drug resistant TB: definitions and epidemiology How does TB become resistant? Current drug susceptibility

More information

Tuberculosis Reference Laboratory, NIDCH, Mahakhali, Dhaka.

Tuberculosis Reference Laboratory, NIDCH, Mahakhali, Dhaka. Bangladesh J Med Microbiol 2011; 05 (02): 06-10 Bangladesh Society of Medical Microbiologists Original Article A rapid Drug Susceptibility Test (DST) for detection of Multi-Drug Resistant (MDR) Mycobacterium

More information

Molecular Epidemiology of Tuberculosis. Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis

Molecular Epidemiology of Tuberculosis. Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis Molecular Epidemiology of Tuberculosis Kathy DeRiemer, PhD, MPH School of Medicine University of California, Davis Overview TB transmission and pathogenesis Genotyping methods Genotyping for clinical management

More information

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics

Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Global Perspective on Transmission: Value in Genotype Mapping of Disease Transmission Dynamics Neel R. Gandhi, MD Emory Rollins School of Public Health January 17, 2013 Medical Research Council BMJ 1948

More information

XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1

XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS. Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma. Pag. 1 XDR TUBERCULOSIS IN EUROPE EPIDEMIOLOGICAL ASPECTS Enrico Girardi Unità di Epidemiologia Clinica INMI Spallanzani, Roma Pag. 1 TB estimated incidence in EUR, 2004 Russian Fed. 12 th among the 22 TB high-burden

More information

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India

Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India AGORA RESEARCH LETTER Compassionate use of bedaquiline in highly drug-resistant tuberculosis patients in Mumbai, India To the Editor: Bedaquiline, a mycobacterial ATP synthase inhibitor [1], is the first

More information

Jillian Dormandy, BS; Akos Somoskovi, MD, PhD; Barry N. Kreiswirth, PhD; Jeffrey R. Driscoll, PhD; David Ashkin, MD; and Max Salfinger, MD

Jillian Dormandy, BS; Akos Somoskovi, MD, PhD; Barry N. Kreiswirth, PhD; Jeffrey R. Driscoll, PhD; David Ashkin, MD; and Max Salfinger, MD Original Research LUNG INFECTION Discrepant Results Between Pyrazinamide Susceptibility Testing by the Reference BACTEC 460TB Method and pnca DNA Sequencing in Patients Infected With Multidrug-Resistant

More information

Patterns of rpoc Mutations in Drug-Resistant Mycobacterium tuberculosis Isolated from Patients in South Korea

Patterns of rpoc Mutations in Drug-Resistant Mycobacterium tuberculosis Isolated from Patients in South Korea ORIGINAL ARTICLE https://doi.org/10.4046/trd.2017.0042 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2018;81:222-227 Patterns of rpoc Mutations in -Resistant Mycobacterium tuberculosis Isolated

More information

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT

MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives. Martie van der Walt TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT TUBERCULOSIS EPIDEMIOLOGY & INTERVENTION RESEARCH UNIT MDR, XDR and Untreatable Tuberculosis and Laboratory Perspectives Martie van der Walt IOM Meeting 15-17 January 2013 introduction 1 min 150 words

More information

Community-Based Surveillance for Drug Resistance of Mycobacterium tuberculosis in Selected Areas in the Philippines

Community-Based Surveillance for Drug Resistance of Mycobacterium tuberculosis in Selected Areas in the Philippines Community-Based Surveillance for Drug Resistance of Mycobacterium tuberculosis in Selected Areas in the Philippines Myrna T. Mendoza, M.D.,* Tessa Tan-Torres, M.D.,* Concepcion F. Ang, R.M.T.,* Rosemarie

More information

Transmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos

Transmissibility, virulence and fitness of resistant strains of M. tuberculosis. CHIANG Chen-Yuan MD, MPH, DrPhilos Transmissibility, virulence and fitness of resistant strains of M. tuberculosis CHIANG Chen-Yuan MD, MPH, DrPhilos Transmissibility, Virulence and Fitness of resistant strains of M. tuberculosis For infectious

More information

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction

11/3/2009 SECOND EDITION Madhukar Pai McGill University. ISTC Training Modules Introduction SECOND EDITION 2009 Madhukar Pai McGill University Introduction 1 Purpose of ISTC ISTC Version 2: Key Points 21 Standards Differ from existing guidelines: standards present what should be done, whereas,

More information

TB 101 Disease, Clinical Assessment and Lab Testing

TB 101 Disease, Clinical Assessment and Lab Testing TB 101 Disease, Clinical Assessment and Lab Testing Pacific Islands Tuberculosis Controllers Association Conference (PITCA) Clinical Laboratory Breakout None Disclosure Objectives Be able to list and explain

More information

The Molecular Epidemiology of Tuberculosis

The Molecular Epidemiology of Tuberculosis The Molecular Epidemiology of Tuberculosis Barry N. Kreiswirth,, PhD Director, PHRI TB Center Airborne pathogen, Mycobacterium tuberculosis Slow grower; doubles 24hrs; 3-4 weeks to culture 3-4 weeks for

More information

The emerging threat of multidrug resistant TB: Global and local challenges and solutions

The emerging threat of multidrug resistant TB: Global and local challenges and solutions Summary of IOM-ASSAf Workshop on: The emerging threat of multidrug resistant TB: Global and local challenges and solutions Salim S. Abdool Karim Pretoria - March, 2010 Why this workshop? Why is it on MDR

More information

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB Sindy M. Paul, MD, MPH, FACPM May 1, 2012 The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB morbidity, including resistance Identifying people

More information

Tuberculosis in Greece: bacteriologically confirmed cases and anti-tuberculosis drug resistance,

Tuberculosis in Greece: bacteriologically confirmed cases and anti-tuberculosis drug resistance, Surveillance and outbreak reports Tuberculosis in Greece: bacteriologically confirmed cases and anti-tuberculosis drug resistance, 1995-2009 D Papaventsis (dpapaventsis@yahoo.gr) 1, S Nikolaou 1, S Karabela

More information

Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR)

Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR) Final Results from Stage 1 of a Double-Blind, Placebo- Controlled Trial with TMC207 in Patients with Multi- Drug Resistant (MDR) Tuberculosis (TB). AH Diacon*, A Pym**, MP Grobusch, G. Churchyard, T De

More information

Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School. I have no financial or other potential conflicts of interest to disclose

Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School. I have no financial or other potential conflicts of interest to disclose Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School I have no financial or other potential conflicts of interest to disclose Update on the epidemiology of TB drug resistance Success

More information

Controlling TB in the era of HIV

Controlling TB in the era of HIV Controlling TB in the era of HIV Christy Hanson, PhD, MPH TB Research Advisor Amy Bloom, MD TB/HIV Advisor TB Incidence rates highest in Africa Estimated new TB cases (all forms) per 100 000 population

More information

TB BASICS: PRIORITIES AND CLASSIFICATIONS

TB BASICS: PRIORITIES AND CLASSIFICATIONS TB CASE MANAGEMENT AND CONTACT INVESTIGATION INTENSIVE MAY 8-11, 2018 TB BASICS: PRIORITIES AND CLASSIFICATIONS LEARNING OBJECTIVES Upon completion of this session, participants will be able to: 1. List

More information

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building

Management of Multidrug- Resistant TB in Children. Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Management of Multidrug- Resistant TB in Children Jennifer Furin, MD., PhD. Sentinel Project, Director of Capacity Building Objectives To review data on best practices for diagnosis, treatment and prevention

More information

TB trends and TB genotyping

TB trends and TB genotyping Management of a TB Contact Investigation for Public Health Workers Albuquerque, NM October 1, 214 TB trends and TB genotyping Marcos Burgos MD October 1, 214 Marcos Burgos, MD has the following disclosures

More information

Evolution of XDR-TB. A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal

Evolution of XDR-TB. A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal Evolution of XDR-TB in KwaZulu-Natal A. Willem Sturm Interim Director K-RITH Nelson R Mandela School of Medicine University of KwaZulu-Natal Drug resistance among culture positive TB cases by South African

More information

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa

Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa 2005 2010 BK Moore 1, E Anyalechi 1, M van der Walt 2, S Smith 1, L Erasmus 3, J Lancaster 2, S Morris 1, N Ndjeka

More information

Rapid detection of multidrug-resistant tuberculosis

Rapid detection of multidrug-resistant tuberculosis Eur Respir J 1997; 10: 1120 1124 DOI: 10.1183/09031936.97.10051120 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 0903-1936 Rapid detection of multidrug-resistant

More information

Treatment of Tuberculosis

Treatment of Tuberculosis Treatment of Tuberculosis, 1940 s Treatment of Tuberculosis ATS/CDC/IDSA Joint Statement 2003 Saskatchewan Lung Association Outline, 2012 Treatment of Tuberculosis Principles of treatment of tuberculosis

More information

Comparison of Pulmonary TB Patients with and without Diabetes Mellitus Type II

Comparison of Pulmonary TB Patients with and without Diabetes Mellitus Type II ORIGINAL ARTICLE Tanaffos (2010) 9(2), 13-20 2010 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran Comparison of Pulmonary TB Patients with and without Diabetes Mellitus Type

More information

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis New TB diagnostics. New drugs.new vaccines Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012 Tuberculosis (TB )is a bacterial disease caused by Mycobacterium tuberculosis (occasionally

More information

THE emergence of multidrug-resistant tuberculosis

THE emergence of multidrug-resistant tuberculosis Vol. 333 No. 14 MULTIDRUG-RESISTANT TUBERCULOSIS IN PATIENTS WITHOUT HIV INFECTION 907 MULTIDRUG-RESISTANT TUBERCULOSIS IN PATIENTS WITHOUT HIV INFECTION EDWARD E. TELZAK, M.D., KENT SEPKOWITZ, M.D., PETER

More information

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Mycobacteria Diagnostic Testing in Manitoba Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline Acknowlegements: Assunta Rendina: Charge Tech HSC Lab Joyce Wolf & Dr. Meenu Sharma: NML Dr. Kanchana

More information

Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal

Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal Hindawi International Scholarly Research Notices Volume 2017, Article ID 1635780, 5 pages https://doi.org/10.1155/2017/1635780 Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant

More information

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis

Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Clinical and Public Health Impact of Nucleic Acid Amplification Tests (NAATs) for Tuberculosis Amit S. Chitnis, MD, MPH; Pennan M. Barry, MD, MPH; Jennifer M. Flood, MD, MPH. California Tuberculosis Controllers

More information

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection? Those oral antibiotics are just not working! Inpatient Standards of Care & Discharge Planning S/He s in the Hospital: Now What Do I Do? Dana G. Kissner, MD TB Intensive Workshop, Lansing, MI 2012 Objectives:

More information

DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION

DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION JOURNAL OF PREVENTIVE MEDICINE 2008; 16(3-4): 3-9 Inviting Editorial DRUG RESISTANCE IN TUBERCULOSIS CONTROL. A GLOBAL AND INDIAN SITUATION Harshad Thakur Centre for Health Policy, Planning and Management,

More information

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY CHAPTER:1 TUBERCULOSIS BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY GLOBAL EMERGENCY: * Tuberculosis kills 5,000 people a day! * 2.3 million die each year!

More information

DNA sequencing for the confirmation of rifampin resistance detected by Cepheid Xpert

DNA sequencing for the confirmation of rifampin resistance detected by Cepheid Xpert JCM Accepted Manuscript Posted Online 4 March 2015 J. Clin. Microbiol. doi:10.1128/jcm.03433-14 Copyright 2015, American Society for Microbiology. All Rights Reserved. 1 2 DNA sequencing for the confirmation

More information

Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment

Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment Multidrug-resistant tuberculosis (MDR-TB): epidemiology, prevention and treatment L. P. Ormerod Chest Clinic, Blackburn Royal Infirmary, Blackburn, Lancs BB2 3LR, and Postgraduate School of Medicine and

More information

Communicable Disease Control Manual Chapter 4: Tuberculosis

Communicable Disease Control Manual Chapter 4: Tuberculosis Provincial TB Services 655 West 12th Avenue Vancouver, BC V5Z 4R4 www.bccdc.ca Communicable Disease Control Manual Definitions Page 1 2.0 DEFINITIONS Many of the definitions that follow are taken from

More information

The ABC s of AFB s Laboratory Testing for Tuberculosis. Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory

The ABC s of AFB s Laboratory Testing for Tuberculosis. Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory The ABC s of AFB s Laboratory Testing for Tuberculosis Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory Laboratory TAT Goals Case Study Specimen Collection Testing Contact

More information

Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology: A Short Review

Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology: A Short Review International Journal of Advanced Microbiology and Health Research www.ijamhr.com Volume 1; Issue 1; September 2017; Page No. 20-24 Review Article Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology:

More information

Fundamentals of Tuberculosis (TB)

Fundamentals of Tuberculosis (TB) TB in the United States Fundamentals of Tuberculosis (TB) From 1953 to 1984, reported cases decreased by approximately 5.6% each year From 1985 to 1992, reported cases increased by 20% 25,313 cases reported

More information

Assessing the programmatic management of drug-resistant TB

Assessing the programmatic management of drug-resistant TB Assessing the programmatic management of drug-resistant TB a. Review the programmatic management of drug-resistant TB patients with the TB manager. i. What is the size of MDR-TB problem locally? How many

More information

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf Desmond Tutu TB Centre Department of Paediatrics and Child Health, Stellenbosch University, and Tygerberg Children s Hospital (TCH) Definitions

More information

Ashraf Tavanaee Sani, 1 Abolfazl Shakiba, 1 Maryam Salehi, 2 Hamid Reza Bahrami Taghanaki, 3 Seiedeh Fatemeh Ayati Fard, 4 and Kiarash Ghazvini 5

Ashraf Tavanaee Sani, 1 Abolfazl Shakiba, 1 Maryam Salehi, 2 Hamid Reza Bahrami Taghanaki, 3 Seiedeh Fatemeh Ayati Fard, 4 and Kiarash Ghazvini 5 BioMed Volume 205, Article ID 747085, 6 pages http://dx.doi.org/0.55/205/747085 Research Article Epidemiological Characterization of Drug Resistance among Mycobacterium tuberculosis Isolated from Patients

More information

Annual surveillance report 2015

Annual surveillance report 2015 Annual surveillance report 215 Acknowledgements The Public Health Agency Northern Ireland gratefully acknowledges all those who contributed to this report, including; physicians, nurses, microbiologists,

More information

Tuberculosis in Estonia with special emphasis on drug-resistant tuberculosis: Notification rate, disease recurrence and mortality

Tuberculosis in Estonia with special emphasis on drug-resistant tuberculosis: Notification rate, disease recurrence and mortality DISSERTATIONES MEDICINAE UNIVERSITATIS TARTUENSIS 207 kai BLÖNDAL Tuberculosis in Estonia with special emphasis on drug-resistant tuberculosis: Notification rate, disease recurrence and mortality DISSERTATIONES

More information

National Survey of Drug-Resistant Tuberculosis in China Dr. Yanlin Zhao

National Survey of Drug-Resistant Tuberculosis in China Dr. Yanlin Zhao National Survey of Drug-Resistant Tuberculosis in China Dr. Yanlin Zhao National Centre for Tuberculosis Control and Prevention of China CDC National TB Reference Laboratory, China CDC BACKGROUND China

More information

TUBERCULOSIS TREATMENT WITH MOBILE-PHONE MEDICATION REMINDERS IN NORTHERN THAILAND

TUBERCULOSIS TREATMENT WITH MOBILE-PHONE MEDICATION REMINDERS IN NORTHERN THAILAND Southeast Asian J Trop Med Public Health TUBERCULOSIS TREATMENT WITH MOBILE-PHONE MEDICATION REMINDERS IN NORTHERN THAILAND Piyada Kunawararak 1, Sathirakorn Pongpanich 2, Sakarin Chantawong 1, Pattana

More information